EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

How do transfusion services manage patients taking therapies such as anti‐ CD38 and anti‐ CD47 known to interfere with red blood cell compatibility testing?

Michael F Murphy iD, Srijana Rajbhandary iD, Sharon Carayiannis, Claudia S Cohn iD

Transfusion · 2024

DOI: 10.1111/trf.17880 ↗

At a glance

Journal article in Transfusion, 2024. Written by Michael F Murphy and 3 co-authors. Institution: NHS Blood and Transplant, Oxford University Hospitals NHS Foundation Trust and the University of Oxford, Oxford, UK. Major MEDLINE topics: Antibodies, Monoclonal, CD47 Antigen, ADP-ribosyl Cyclase 1, Antibodies, Monoclonal, Humanized. Cited 5 times so far (Crossref); 4 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Drugs such as daratumumab (Darzalex, anti‐CD38) and Hu5F9‐G4 (magrolimab, anti‐CD47) may interfere with red blood cell compatibility testing as CD38 and CD47 are expressed on red blood cells. Study Design and Methods A survey of AABB member transfusion services was undertaken to understand their experiences of managing patients taking therapeutic monoclonal antibodies that are known to interfere with blood grouping and compatibility testing.

Results

The survey was distributed to the contact person at US‐based AABB member transfusion services. The response rate was 27%. 172 of 240 (72%) indicated they had difficulties in performing compatibility testing in patients taking daratumumab and 66 of 91 (73%) reported difficulties in performing compatibility testing in patients taking magrolimab. Actions taken to provide compatible blood for these patients included referral of all samples to a reference center, blood group pheno/genotyping the patient in advance of starting the drug, treating reagent cells with 0.2 M dithiothreitol and using K‐negative red cell units for patients taking daratumumab, and Gamma‐clone (Immucor) anti‐IgG for indirect antiglobulin testing for patients taking magrolimab. Lack of communication from clinical services about drug treatment was identified as a concern.

Conclusion

The results of the survey demonstrate that transfusion services are having challenges with the transfusion management of patients taking therapeutic monoclonal antibodies, and further education is needed.

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalCD47 AntigenADP-ribosyl Cyclase 1Antibodies, Monoclonal, HumanizedHumansBlood Grouping and CrossmatchingErythrocytesBlood Group IncompatibilityBlood TransfusionSurveys and QuestionnairesMembrane Glycoproteins

Author keywords

ABO typing interferenceDarzalexHu5F9‐G4anti‐CD38anti‐CD47daratumumabmagrolimabpretransfusion testing interferenceserological interferencetransfusion interference

Substances

Antibodies, MonoclonalCD47 AntigendaratumumabADP-ribosyl Cyclase 1Antibodies, Monoclonal, HumanizedCD47 protein, humanCD38 protein, humanMembrane Glycoproteins

Authors and institutions

  • NHS Blood and Transplant, Oxford University Hospitals NHS Foundation Trust and the University of Oxford, Oxford, UK.
  • AABB, Bethesda, Maryland, USA.
  • Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID profiles: Michael F Murphy, Srijana Rajbhandary, Claudia S Cohn

Cite

APA

Murphy, M. F., Rajbhandary, S., Carayiannis, S., & Cohn, C. S. (2024). How do transfusion services manage patients taking therapies such as anti‐ CD38 and anti‐ CD47 known to interfere with red blood cell compatibility testing?. Transfusion. https://doi.org/10.1111/trf.17880

Vancouver

Murphy MF, Rajbhandary S, Carayiannis S, Cohn CS. How do transfusion services manage patients taking therapies such as anti‐ CD38 and anti‐ CD47 known to interfere with red blood cell compatibility testing?. Transfusion. 2024. doi:10.1111/trf.17880

BibTeX
@article{Murphy2024,
  author = {Murphy, Michael F and Rajbhandary, Srijana and Carayiannis, Sharon and Cohn, Claudia S},
  title = {How do transfusion services manage patients taking therapies such as anti‐ CD38 and anti‐ CD47 known to interfere with red blood cell compatibility testing?},
  journal = {Transfusion},
  year = {2024},
  doi = {10.1111/trf.17880}
}
Start for free →